In this comprehensive presentation, Adam D. Cohen, MD, Director of the Myeloma Immunotherapy Program at the Abramson Cancer Center reviews the clinical trials and advances in myeloma therapy. Dr Cohen's overview includes the monoclonal antibodies, vaccines in early development and cellular therapies, with commentary on the PD-1/PD-L1 inhibitors, the DC/MM fusion vaccine plus anti-PD1 therapy post-ASCT, CART19 salvage autoSCT therapy and the validation of BCMA-specific CAR in relapsed/refractory multiple myeloma.
Related Links
Published
December 6, 2016
Created by
BROADCASTMED